RhPTH (1-34) ( DrugBank: rhPTH )


1 disease
IDDisease name (Link within this page)Number of trials
70Spinal stenosis1

70. Spinal stenosis


Clinical trials : 96 Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-006152-36-DK
(EUCTR)
10/05/201210/05/2012Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing?Postoperative treatment with parathyroidea hormone Forteo® inpatients undergoing posterolateral spinal fusion surgery. A prospektiveand a randomized double-blinded, placebo-controlled study - PTH-U-DESE-STUDY Spinal stenosis
MedDRA version: 14.1;Level: LLT;Classification code 10041597;Term: Spinal stenosis of lumbar region;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Forteo
Product Name: Forsteo
Product Code: 0002-8971
INN or Proposed INN: teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34)
Other descriptive name: rhPTH (1-34)
Middelfart RygsektorNULLNot RecruitingFemale: yes
Male: yes
100Phase 2Denmark